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R1006Regardless of the molecular
mechanism, the functional significance
of stabilizing actin appears clear.
Actin is a major consumer of ATP [19]
and the observed stabilization of actin
filaments therefore prevents the
consumption of ATP, whilst retaining
actin filaments and their polarity. This
polarity retention may be important to
allow growth using the existing
cytoskeleton with minimal ATP
consumption, if the post-starvation
environment provides enough nutrients
for growth.
This new work provides tantalizing
insights into previously unrecognized
responses to starvation. However,
these findings raise nearly as many
questions as they answer. A key
question is why only extreme energy
stress induces the rigor-like state
and whether this relates to cargo
release. It will also be important to
understand if the type V myosin
responses are important for conserving
energy or if the cargo-free rigor-like
state provides some other advantage
for adaptation to starvation. It will
also be worth exploring whether
the type V myosin responses
are conserved and what advantage
this might provide to mammalian
cells that are more dependent on
microtubules for polarized transport.
In contrast, the advantage of the
stabilization of actin is apparent,
although the molecular mechanism
inducing stabilization in yeast and
mammalian cells needs to beelucidated. Further investigation into
the role and regulation of these two
new responses will provide a clearer
picture of how the cell overcomes the
challenge of energy starvation.
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Delivery or Eating Locally?Parkinson’s disease-associated PINK1 and Parkin maintain mitochondrial
health through promoting mitophagy, the autophagic removal of damaged
mitochondria, in non-neuronal cells. Whether they do so in neurons has been
controversial. A new study aims to resolve the controversy.Bingwei Lu
Mitochondria play essential roles in
many aspects of cellular physiology,
from energy production and
intermediary metabolism to apoptosis
[1]. Proper mitochondrial function is
particularly important for the health
of neurons, as suggested by the
prominent manifestation ofneurological impairments in
mitochondrial diseases [2].
Mitochondrial dysfunction has been
observed in many of the age-related
neurodegenerative diseases, including
Alzheimer’s disease and Parkinson’s
disease (PD) [2]. However, the origin
of the mitochondrial dysfunction in
most of these diseases remains
elusive. Pten-induced kinase 1(PINK1) and Parkin, two genes linked
to familial PD, have been implicated
in mitochondrial quality control,
specifically the promotion of
mitochondrial degradation by
autophagy — mitophagy. Many of
the studies indicating a function for
PINK1 and Parkin in mitophagy
were carried out in cultured
non-neuronal cells, but a new study
published in the Journal of Cell
Biology [3] now suggests that PINK1
and Parkin can indeed act in neuronal
axons to remove damaged
mitochondria.
PD is the most common movement
disorder and the secondmost common
neurodegenerative disease after
Alzheimer’s disease. It is characterized
by rather selective degeneration of
Dispatch
R1007dopaminergic neurons in substantia
nigra of the midbrain, although other
brain regions can also be affected. The
cause of degeneration of dopaminergic
neurons is presumably diverse, with
mitochondrial dysfunction, protein
misfolding, oxidative stress, and
endoplasmic reticulum stress having
been implicated [4]. That mitochondrial
dysfunction plays a causal role in PD
pathogenesis is supported by the
observations that mitochondrial toxins,
such asMPTP and rotenone, can cause
PD-like symptoms in humans and
animal models [5], and that mutations
in PINK1, a mitochondria-targeted
serine/threonine kinase, cause early
onset familial PD [6]. Genetic studies in
Drosophila first established that PINK1
and Parkin act in a common pathway to
maintain mitochondrial health, with
PINK1 acting upstream of Parkin [7–9].
Work from the Youle laboratory
offered a key clue on the mechanism of
action of the PINK1–Parkin pathway in
this process. They showed that Parkin,
a normally cytosolic protein, is
recruited in a PINK1-dependent
manner to dysfunctional mitochondria,
which are characterized by reduced
membrane potential [10]. Parkin
induces broad ubiquitination and
degradation of mitochondrial outer
membrane proteins [11]. The prevailing
view is that these ubiquitinated
proteins serve as an ‘eat me’ signal on
damaged mitochondria that is
recognized by ubiquitin-binding
adaptor proteins, which recruit the
autophagy machinery and induce
mitophagy. This mitophagy model of
PINK1–Parkin action is attractive for
its simplicity and explanatory power,
and the experimental system
used (treatment of HeLa cells
overexpressing YFP–Parkin with the
mitochondrial toxin CCCP) has been
widely adopted by investigators in the
field. However, it remains to be seen
whether Parkin-mediated mitophagy is
essential for the maintenance of a
healthy pool of mitochondria in
neurons under steady-state conditions
in intact animals.
A few studies carried out in cultured
mammalian primary cortical neurons or
in induced pluripotent stem cell (iPSC)-
derived human dopaminergic neurons
have generated conflicting results
regarding the role of PINK1–Parkin in
handling mitochondrial damage. An
initial study failed to observe Parkin
translocation and mitophagy in
CCCP-treated mouse cortical neurons[12], whereas later studies found that,
under different culture conditions,
Parkin translocation to damaged
mitochondria can occur and that
mitophagy can be observed in neuronal
soma [13,14]. To complicate things
further, studies in iPSC-derived human
dopaminergic neurons showed that
mitochondrial damage failed to induce
mitophagy, even when Parkin was
overexpressed [15,16]. Thus, whether
neurons, especially the disease-
relevant dopaminergic neurons,
undergo PINK1–Parkin-dependent
mitophagy in response to
mitochondrial damage remains
unclear.
Previous studies of neuronal
mitophagy used global application of
the mitochondrial toxins CCCP, a
chemical uncoupler, or valinomycin, a
potassium ionophore, both of which
trigger loss ofmitochondrial membrane
potential. In the new study [3], Ashrafi
et al. used two methods to induce
localized damage to axonal
mitochondria. In the first method, a
genetically encoded photosensitizer —
mitochondria-targeted KillerRed
(mt-KR) — was employed.
Light-induced activation of mt-KR
causes reactive oxygen species (ROS)-
mediated damage to mitochondria. In
the second method, microfluidic local
perfusion chambers were used to
induce mitochondrial depolarization in
axonal segments via perfusion of
actinomycin A, an inhibitor of
respiratory complex III and a less toxic
compound than CCCP. The authors
observed that axonal mitochondria
damaged by mt-KR or actinomycin A
colocalize with autophagosomes and
lysosomes, suggesting that mitophagy
is initiated in distal axons. This
contrasts with findings from a
previous study, which observed
neuronal mitophagy primarily in the
somatodendritic compartment, but this
observation was made at much later
time points after drug treatment than
those used in the current study [13].
To explore the mechanism of the
observed mitophagy in their
experimental settings, Ashrafi et al. [3]
turned to the PINK1–Parkin pathway. A
key step in the PINK1–Parkin-regulated
mitophagy process is the recruitment
of Parkin to damaged mitochondria.
Although available antibodies have so
far failed to detect recruitment of
endogenous Parkin to mitochondria,
the authors were able to observe
Parkin recruitment to mt-KR- oractinomycin-damaged mitochondria
by using low-level expression of a
YFP–Parkin reporter. Furthermore,
using cultured neurons derived from
parkin-/- mice, they found that the
recruitment of autophagosomes to
damaged axonal mitochondria was
abolished. Similarly, using cultured
neurons derived from pink1-/- rats, the
authors showed that the recruitment of
Parkin and autophagosomes to
damaged axonal mitochondria is
PINK1 dependent. Thus, the
PINK1–Parkin pathway previously
defined in flies appears to be operating
in axons of mammalian neurons to
promote mitophagy. The implication of
this finding is immense. It suggests that
axons, and possibly dendrites, are key
subcellular sites of action of the
PINK1–Parkin pathway, potentially
reflecting the particularly high demand
for energy production and calcium
buffering by these sites. When the
PINK1–Parkin pathway is impaired,
damaged mitochondria at these sites
may cause synaptic dysfunction,
one of the earliest signs of
neurodegeneration.
In addition to the questions it
answered, many further questions are
raised by this study. One of the key
observations of this study is that Parkin
is recruited to only a portion of the
depolarized mitochondria and that
even fewer mitochondria are engulfed
by autophagosomes. This may reflect
a stochastic onset of mitophagy
caused by the presumably limited
supply of PINK1, Parkin, or the
autophagy machinery in neuronal
axons. Alternatively, this may reflect
functional heterogeneity of neuronal
mitochondria and their differential
responses to experimentally induced
damage. Perhaps, after similar
mt-KR- or actinomycin-inflicted insults,
more robust mitochondria can be
rescued by repair, whereas the ‘old’ or
‘worn-out’ mitochondria will be
damaged beyond repair and subjected
to autophagic removal. If this were the
case, it would be exciting to test
whether mitochondrial repair and
biogenesis can also occur locally in
axons. The conventional wisdom is that
most mitochondrial biogenesis-related
events occur in the soma, but this
remains to be rigorously tested.
Related to this point, previous studies
in other experimental settings [17] have







Figure 1. Possible fates of axonal mitochondria.
(A) Healthy mitochondria (green) are transported anterogradely to nerve terminals where they
will perform essential synaptic and neuronal functions. (B) Mildly damaged mitochondria
(yellow) are transported retrogradely to the soma, where they will be repaired back to healthy
mitochondria or removed by mitophagy, both presumably through the PINK1–Parkin pathway.
(C) Severely damaged mitochondria (red) are engulfed by autophagosomes locally in neuronal
axons. The mitoautophagosomes may fuse with lysosomes locally in axons to degrade the
mitochondrial content or be transported to the soma for fusion with lysosomes and degrada-
tion of mitochondrial content. The length of the purple arrows under the green and yellow
mitochondria in the axon indicates the relative strength of their anterograde (right) vs. retro-
grade (left) transport.
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mitochondria will presumably
accumulate in the soma, where they
may be repaired or removed [18].
Intriguingly, Ashrafi et al. [3] find that
most of the damaged mitochondria
that recruit autophagosomes are
stationary. However, not all of these
mitoautophagosomes fuse with
lysosomes during the observation
period, raising the possibility that some
of them may eventually be returned to
the soma via retrograde transport. This
would reconcile with an earlier report of
PINK1–Parkin-mediated mitophagy in
neuronal soma observed at later time
points [13], and also be consistent with
the earlier observation of mitochondria
in moving autophagosomes [19]. It is
even possible that the formation of the
mitoautophagosomes in neuronal
axons may indicate a traffic-redirection
mechanism in which damaged
mitochondria are dislodged from
the microtubule motor-based
mitochondria transport system and get
connected to the autophagosome
transport system. Further studies of the
transport systems associated with
damaged mitochondria will test this
hypothesis. Finally, it will be important
to test whether the PINK1–Parkin-
directed mitophagy pathway operates
in vivo in neuronal axons, especially
those of disease-susceptible
dopaminergic neurons, in disease
models or in aged normal animals. This
is an urgent task considering that thePINK1–Parkin pathway is particularly
important for the survival and function
of these neurons, yet studies in
iPSC-derived human dopaminergic
neurons have so far failed to reveal
Parkin-mediated mitophagy [16], and
in vivo studies in mice showed that
dysfunctional and depolarized
mitochondria in dopaminergic neurons
are not removed by Parkin-mediated
mitophagy [20]. Thus, the key
mechanism of action of the
PINK1–Parkin pathway in
dopaminergic neurons remains a major
unanswered question, the answer to
which could have significant
therapeutic implications.References
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